IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2443 
Small font sizeDefault font sizeIncrease font size
Navigate Here
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (223 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

In This Article
 »  References

 Article Access Statistics
    PDF Downloaded431    
    Comments [Add]    
    Cited by others 31    

Recommend this journal


 Table of Contents    
Year : 2013  |  Volume : 45  |  Issue : 5  |  Page : 536-537

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis

Department of Pharmacology, Government Medical College, Surat, Gujarat, India

Date of Web Publication6-Sep-2013

Correspondence Address:
Shashank Deoghare
Department of Pharmacology, Government Medical College, Surat, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0253-7613.117765

Rights and Permissions

How to cite this article:
Deoghare S. Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis. Indian J Pharmacol 2013;45:536-7

How to cite this URL:
Deoghare S. Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis. Indian J Pharmacol [serial online] 2013 [cited 2023 May 28];45:536-7. Available from: https://www.ijp-online.com/text.asp?2013/45/5/536/117765


The Food and Drug Administration (FDA), on 28 December 2012, granted accelerated approval to SIRTURO™ (bedaquiline) Tablets as a part of combination therapy in adults with multi-drug-resistant TB (MDR-TB). [1] It is the first new anti-TB drug to be approved after 1998 (rifapentine was approved in 1998) and the first anti-TB drug with a novel mechanism of action to be approved after 40 years (rifampicin was approved in 1974). [2] It is also the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs. [1]

MDR-TB is an infection with a strain of Mycobacterium tuberculosis that is resistant to isoniazid and rifampin, the two most potent first-line anti-TB drugs. MDR-TB has emerged as a serious health threat globally. It affected nearly 630,000 people in 2011, and incidence is increasing in many parts of the world. Unlike Drug-sensitive TB (DS-TB), the treatment of MDR-TB is more complex, requires intense chemotherapy, extensive monitoring and is considerably costly. Use of existing less efficacious second-line drugs is associated with greater side-effects. [3]

Bedaquiline, a diarylquinoline, binds to subunit c of mycobacterial ATP synthase (an enzyme essential for the energy production in M. tuberculosis) and inhibits its activity. [4] It is highly selective for mycobacterial ATP synthase enzyme compared to homologous eukaryotic enzyme (Selectivity Index >20 000). Thus, it is less likely to produce target-based toxicity in the host cells. [5] Due to an entirely new mechanism of action, bedaquiline belongs to a novel class of anti-TB compounds. The distinct target and unique mode of action of bedaquiline reduces the potential for cross-resistance with the existing anti-TB drugs. It is active against DS, MDR, Pre-XDR, and XDR strains of M. tuberculosis in vitro. [6]

Bedaquiline is available as 100 mg tablet for oral administration. Its bioavailability is enhanced in presence of food. It is highly plasma protein bound (>99%) and shows tri-exponential decline in plasma concentration with effective half-life of approximately 24-30 hours and terminal half-life (t 1/2 , term) of approximately 4-5 months. It is metabolized by CYP3A4 to N-monodesmethyl metabolite, which is 4-6 times less potent than the parent drug. Enzyme inducers can reduce the efficacy of bedaquiline, whereas enzyme inhibitors can predispose to its adverse reactions. It is eliminated mainly in feces. [7]

Bedaquiline should be administered as directly observed therapy (DOT) along with standard MDR-TB regimen. Recommended dose is 400 mg once daily for 2 weeks followed by 200 mg thrice weekly for 22 weeks. After 24 weeks of bedaquiline therapy, MDR-TB regimen should be continued as per national TB treatment guidelines. [7]

The most common side-effects reported with bedaquiline therapy are nausea (30%), arthralgia (26%), headache (22%), hemoptysis (14%), chest pain (9%), anorexia (7%), and rash (6%). Important cardiovascular adverse effect is QT prolongation. Concurrent use of other QT-prolonging drugs causes additive QT prolongation. Other important adverse effect is elevation of hepatic transaminases, which is moderate and reversible on discontinuation of therapy. [7] There are no clinical data in pediatric patients, adolescents (<18 yrs), and pregnant and lactating women. The safety and efficacy of bedaquiline for treatment of drug-sensitive TB, extra-pulmonary TB, and HIV-infected patients is not established. Therefore, use of bedaquiline is not recommended in these settings. [7]

What Is an Accelerated Approval?

The accelerated approval program allows FDA to approve a drug for treatment of a serious or life-threatening disease on the basis of clinical data establishing the effect of drug on surrogate endpoints that reasonably predict clinical benefit. Thus, patients get earlier access to promising new drugs. However, the company has to conduct further clinical studies to verify efficacy and safety of the drug to get traditional approval from FDA. [8]

The accelerated approval to bedaquiline is based on its effect on surrogate endpoint of time to sputum culture conversion in two phase II clinical trials (C208 and C209). C208 was a randomized, double-blind, placebo-controlled trial with two consecutive but separate stages (stage 1 and 2). In this trial, subjects with sputum smear-positive MDR-TB were assigned to either bedaquiline or placebo along with background regimen of other anti-TB drugs. The primary endpoint of this study was time to sputum culture conversion (SCC) defined as time required for two consecutive negative sputum cultures after start of therapy. The secondary endpoint was culture conversion rate at 24 weeks. Results of C208 demonstrated a median time of 83 days for SCC with bedaquiline combination therapy compared to 125 days in placebo combination therapy. Culture conversion rate at the end of 24 weeks was 79 percent in bedaquiline treatment group compared to 58 percent in the placebo treatment group. In an open label C 209 study, which is still ongoing, sputum smear-positive subjects with MDR-TB received bedaquiline with background regimen of anti-TB drugs (no placebo group). Primary and secondary endpoints were same as previous study. In C209 trial, the median time to SCC was 57 days and a culture conversion rate was 80 percent further supporting the efficacy findings. [9]

Phase III trial of bedaquiline is planned to confirm the efficacy findings from previous phase II clinical trials and to obtain additional safety data. Bedaquiline will get traditional FDA approval if results of phase III trial confirm that the drug actually provides clinical benefit. [9] FDA speculates that bedaquiline has the potential to fulfill an unmet medical need for the treatment of MDR-TB and will reduce the risk of development of resistance to other anti-TB drugs in the standard regimen.

 » References Top

1.FDA news release. 2012 Dec 31. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm [Last accessed on 2013 Feb 15].  Back to cited text no. 1
2.National Research Council. Ending neglect: The elimination of tuberculosis in the United States. Washington, DC: The National Academies Press; 2000.  Back to cited text no. 2
3.World Health Organization (WHO). Global Tuberculosis Report 2012. Available from: http://www.who.int/tb/publications/global_report/gtbr12_main.pdf [Last accessed on 2013 Feb 15].  Back to cited text no. 3
4.Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3:323-24.  Back to cited text no. 4
5.Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53:1290-2.  Back to cited text no. 5
6.Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202-04.  Back to cited text no. 6
7.U.S. Food and Drug Administration. SIRTURO Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf [Last accessed on 2013 Jun 23].  Back to cited text no. 7
8.U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21 Part 314 Subpart H. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart = 314andshowFR = 1andsubpartNode = 21: [Last accessed on 2013 June 23].  Back to cited text no. 8
9.U.S. Food and Drug Administration. NDA 204-384 Deputy Division Director Summary Review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000SumR.pdf [Last accessed on 2013 June 23].  Back to cited text no. 9

This article has been cited by
1 In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor
Rajesh Mondal, Azger Dusthackeer V. N., Palaniyandi Kannan, Amit Kumar Singh, Kannan Thiruvengadam, Radhakrishnan Manikkam, Shainaba A. S., Mahizhaveni Balasubramanian, Padmasini Elango, Sam Ebenezer Rajadas, Dinesh Bharadwaj, Gandarvakottai Senthilkumar Arumugam, Suresh Ganesan, Hemanth Kumar A. K., Manjula Singh, Shripad Patil, Jaleel U. C. A., Mukesh Doble, Balagurunathan R., Srikanth Prasad Tripathy, Vanaja Kumar, Frederick Quinn
PLOS ONE. 2023; 18(3): e0282454
[Pubmed] | [DOI]
2 Aromatic or Hetero-aromatic Directly Attached Tri and Tetrasubstituted Methanes: New Chemical Entities as Anti-Infectives
Deblina Roy, Ritesh P. Thakare, Sidharth Chopra, Gautam Panda
Current Medicinal Chemistry. 2023; 30(8): 974
[Pubmed] | [DOI]
3 Discovery and Development of Antibacterial Agents: Fortuitous and Designed
Ravleen Kaur, Pooja Rani, Atanas G. Atanasov, Qushmua Alzahrani, Reena Gupta, Bhupinder Kapoor, Monica Gulati, Pooja Chawla
Mini-Reviews in Medicinal Chemistry. 2022; 22(7): 984
[Pubmed] | [DOI]
4 Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis
Clement K. M. Tsui, Flavia Sorrentino, Gagandeep Narula, Alfonso Mendoza-Losana, Ruben Gonzalez del Rio, Esther Pérez Herrán, Abraham Lopez, Adama Bojang, Xingji Zheng, Modesto Jesus Remuiñán-Blanco, Yossef Av-Gay
Molecules. 2022; 27(14): 4446
[Pubmed] | [DOI]
Rani. A. Shinde, Vasanti. M. Suvarna, Arundhati. N. Abhyankar
Indian Drugs. 2022; 59(01): 7
[Pubmed] | [DOI]
6 Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis
Anuradha T Deshkar, Prashant A Shirure
Cureus. 2022;
[Pubmed] | [DOI]
7 Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis
Nitin Verma, Vimal Arora, Rajendra Awasthi, Yinghan Chan, Niraj Kumar Jha, Komal Thapa, Talha Jawaid, Mehnaz Kamal, Gaurav Gupta, Gang Liu, Keshav Raj Paudel, Philip Michael Hansbro, Brian Gregory George Oliver, Sachin Kumar Singh, Dinesh Kumar Chellappan, Harish Dureja, Kamal Dua
Journal of Drug Delivery Science and Technology. 2022; : 103690
[Pubmed] | [DOI]
8 Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives
Minhua Chen, Zhangxuan Shou, Xue Jin, Yingjun Chen
Drug Delivery. 2022; 29(1): 2442
[Pubmed] | [DOI]
9 The respiratory lipoquinone, menaquinone, functions as an inducer of genes regulated by the Mycobacterium smegmatis repressor MSMEG_2295
Anik Barman, Madhu Manti Patra, Sujoy K. Das Gupta
Microbiology . 2022; 168(5)
[Pubmed] | [DOI]
10 The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives
Navisha Dookie, Senamile L. Ngema, Rubeshan Perumal, Nikita Naicker, Nesri Padayatchi, Kogieleum Naidoo
Clinical Microbiology Reviews. 2022;
[Pubmed] | [DOI]
11 Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead
Samira Tarashi, Seyed Davar Siadat, Abolfazl Fateh, Fu-Ming Tsai
BioMed Research International. 2022; 2022: 1
[Pubmed] | [DOI]
12 A Test System for in vitro Screening Antimycobacterial Drug Candidates for MmpS5-MmpL5 Mediated Resistance
K. V. Shur, S. G. Frolova, N. I. Akimova, V. N. Danilenko, D. A. Maslov
Russian Journal of Genetics. 2021; 57(1): 114
[Pubmed] | [DOI]
13 The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection
Gen Li, David M.P. De Oliveira, Mark J. Walker
Journal of Inorganic Biochemistry. 2021; : 111661
[Pubmed] | [DOI]
14 Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance
Mark Laws, Peiqin Jin, Khondaker Miraz Rahman
Trends in Microbiology. 2021;
[Pubmed] | [DOI]
15 Applicability of Chromatographic Co-Elution for Antibiotic Target Identification
Sina Schäkermann, Dominik Wüllner, Abdulkadir Yayci, Andrew Emili, Julia Elisabeth Bandow
PROTEOMICS. 2021; 21(1): 2000038
[Pubmed] | [DOI]
16 Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
Jinmeng Li, Gaoyi Yang, Qingshan Cai, Yu Wang, Yingying Xu, Ruoying Zhang, Yazhen Lang, Xinjun Cai
International Journal of Infectious Diseases. 2021; 110: 179
[Pubmed] | [DOI]
17 Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin
Katijah Khoza-Shangase, Marina Prodromos
South African Journal of Communication Disorders. 2021; 68(1)
[Pubmed] | [DOI]
18 An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
Mahanjit Konwar, MiteshR Maurya, TusharB Nishandar, UrmilaM Thatte, NithyaJ Gogtay
Perspectives in Clinical Research. 2021; 12(3): 159
[Pubmed] | [DOI]
19 A review of current and promising nontuberculous mycobacteria antibiotics
Christophe R Cantelli, Alexandra Dassonville-Klimpt, Pascal Sonnet
Future Medicinal Chemistry. 2021; 13(16): 1367
[Pubmed] | [DOI]
20 Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era
Alina Minias, Lidia Zukowska, Ewelina Lechowicz, Filip Gasior, Agnieszka Knast, Sabina Podlewska, Daria Zygala, Jaroslaw Dziadek
Frontiers in Microbiology. 2021; 11
[Pubmed] | [DOI]
21 Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada
Kayley D. McCubbin, R. Michele Anholt, Ellen de Jong, Jennifer A. Ida, Diego B. Nóbrega, John P. Kastelic, John M. Conly, Matthias Götte, Tim A. McAllister, Karin Orsel, Ian Lewis, Leland Jackson, Graham Plastow, Hans-Joachim Wieden, Kathy McCoy, Myles Leslie, Joan L. Robinson, Lorian Hardcastle, Aidan Hollis, Nicholas J. Ashbolt, Sylvia Checkley, Gregory J. Tyrrell, André G. Buret, Elissa Rennert-May, Ellen Goddard, Simon J. G. Otto, Herman W. Barkema
Frontiers in Public Health. 2021; 9
[Pubmed] | [DOI]
22 Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics
Bismillah Mubeen, Aunza Nayab Ansar, Rabia Rasool, Inam Ullah, Syed Sarim Imam, Sultan Alshehri, Mohammed M. Ghoneim, Sami I. Alzarea, Muhammad Shahid Nadeem, Imran Kazmi
Antibiotics. 2021; 10(12): 1473
[Pubmed] | [DOI]
23 Two Decades of TB Drug Discovery Efforts—What Have We Learned?
Balachandra Bandodkar, Radha Krishan Shandil, Jagadeesh Bhat, Tanjore S. Balganesh
Applied Sciences. 2020; 10(16): 5704
[Pubmed] | [DOI]
24 Bedaquiline: A Mini Review
Nandhini Saravanabavan, Padmavathi Shanmuganathan, Manimekalai Kumarappan
Annals of SBV. 2020; 8(1): 2
[Pubmed] | [DOI]
25 Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives
Elliasu Y. Salifu, Clement Agoni, Fisayo A. Olotu, Mahmoud E.S. Soliman
Computational Biology and Chemistry. 2020; 85: 107204
[Pubmed] | [DOI]
26 Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives
Tom Armstrong, Malcolm Lamont, Alice Lanne, Luke J. Alderwick, Neil R. Thomas
Bioorganic & Medicinal Chemistry. 2020; 28(22): 115744
[Pubmed] | [DOI]
27 Screening of natural compounds that targets glutamate racemase of Mycobacterium tuberculosis reveals the anti-tubercular potential of flavonoids
Alka Pawar, Prakash Jha, Madhu Chopra, Uma Chaudhry, Daman Saluja
Scientific Reports. 2020; 10(1)
[Pubmed] | [DOI]
28 Multitarget Approaches against Multiresistant Superbugs
Declan Alan Gray, Michaela Wenzel
ACS Infectious Diseases. 2020; 6(6): 1346
[Pubmed] | [DOI]
29 Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
Sara Consalvi, Cristina Scarpecci, Mariangela Biava, Giovanna Poce
Bioorganic & Medicinal Chemistry Letters. 2019; 29(23): 126731
[Pubmed] | [DOI]
30 Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’
Yoshiaki Takahashi, Masayuki Igarashi
The Journal of Antibiotics. 2018; 71(1): 4
[Pubmed] | [DOI]
31 The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis
Danielle D. Barnes, Mimmi L. E. Lundahl, Ed C. Lavelle, Eoin M. Scanlan
ACS Chemical Biology. 2017; 12(8): 1969
[Pubmed] | [DOI]


Print this article  Email this article


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow